{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:45:01Z","timestamp":1793781901011,"version":"4.6.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Kiki Fund for Breast Cancer Leptomeningeal Metastases Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Leptomeningeal disease (LMD) is a relatively uncommon manifestation of advanced cancer. Patients with LMD carry a poor prognosis and often decline rapidly, complicating inclusion in clinical trials. Identification of LMD subsets of greater incidence and more favorable prognosis might facilitate dedicated clinical trials in the future. We hypothesized that patients with breast cancer may represent such a population and sought to assess the relative incidence and prognosis of LMD secondary to breast vs. non-breast primaries.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We identified 2411 patients with intracranial metastases secondary to breast (N\u00a0=\u00a0501) and non-breast (N\u00a0=\u00a01910) primaries at Brigham and Women\u2019s Hospital\/Dana-Farber Cancer Institute between 1996 and 2020, of whom 112 presented with and an additional 161 subsequently developed LMD. A\u00a0log-rank test and Cox modeling were used to compare outcomes in patients with breast vs. non-breast primaries.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among patients with newly diagnosed intracranial disease, the incidence proportion of concurrent LMD was 11.4% vs. 2.9% among patients with breast vs. non-breast primaries (P\u00a0&amp;lt;\u00a0.001). Development of LMD among initially LMD-na\u00efve patients was also more common among patients with breast vs. non-breast primaries (HR\u00a0=\u00a01.49 [1.05\u20132.11], P\u00a0=\u00a0.03). Patients with LMD secondary to breast vs. non-breast primaries displayed lower all-cause mortality (HR 0.70 [0.52\u20130.93], P\u00a0=\u00a0.01; median survival: 5.2 vs. 2.4\u00a0months, respectively), with a greater numerical difference observed in patients with LMD at intracranial involvement (7.4 vs. 2.6\u00a0months, respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients with breast cancer and LMD may represent an ideal population for clinical trials given the higher incidence and potentially more favorable prognosis seen in this population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/neuonc\/noac249","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T18:00:49Z","timestamp":1668189649000},"page":"973-983","source":"Crossref","is-referenced-by-count":25,"title":["Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2598-6529","authenticated-orcid":false,"given":"Nayan","family":"Lamba","sequence":"first","affiliation":[{"name":"Harvard Radiation Oncology Program, Harvard University , Boston, Massachusetts , USA"},{"name":"Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women\u2019s Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel N","family":"Cagney","sequence":"additional","affiliation":[{"name":"Mater Private Hospital , Dublin , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J","family":"Catalano","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Harvard T.H. Chan School of Public Health, and Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Elhalawani","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women\u2019s Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne A","family":"Haas-Kogan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women\u2019s Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y","family":"Wen","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber\/Brigham and Women\u2019s Cancer Center, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Wagle","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy U","family":"Lin","sequence":"additional","affiliation":[{"name":"Breast Oncology Program, Dana-Farber Cancer Institute , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayal A","family":"Aizer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women\u2019s Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam","family":"Tanguturi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women\u2019s Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"issue":"9","key":"2023050411180790600_CIT0001","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/neuonc\/noab101","article-title":"Epidemiology of brain metastases and leptomeningeal disease","volume":"23","author":"Lamba","year":"2021","journal-title":"Neuro Oncol."},{"issue":"7","key":"2023050411180790600_CIT0002","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamaoncol.2018.0813","article-title":"Implications of screening for brain metastases in patients with breast cancer and non-small cell lung cancer","volume":"4","author":"Cagney","year":"2018","journal-title":"JAMA Oncol."},{"issue":"21","key":"2023050411180790600_CIT0003","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","article-title":"Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial","volume":"295","author":"Aoyama","year":"2006","journal-title":"JAMA."},{"issue":"4","key":"2023050411180790600_CIT0004","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jama.2016.9839","article-title":"Effect of Radiosurgery alone vs Radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial","volume":"316","author":"Brown","year":"2016","journal-title":"JAMA."},{"issue":"17","key":"2023050411180790600_CIT0005","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1001\/jama.280.17.1485","article-title":"Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial","volume":"280","author":"Patchell","year":"1998","journal-title":"JAMA."},{"issue":"2","key":"2023050411180790600_CIT0006","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study","volume":"29","author":"Kocher","year":"2011","journal-title":"J Clin Oncol."},{"issue":"2","key":"2023050411180790600_CIT0007","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2016.10.005","article-title":"Stereotactic radiotherapy of the tumor bed compared to whole brain radiotherapy after surgery of single brain metastasis: results from a randomized trial","volume":"121","author":"K\u0119pka","year":"2016","journal-title":"Radiother Oncol."},{"issue":"8","key":"2023050411180790600_CIT0008","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicentre, randomised, controlled, phase 3 trial","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol."},{"issue":"5","key":"2023050411180790600_CIT0009","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jamaoncol.2018.7204","article-title":"Association of neurosurgical resection with development of Pachymeningeal seeding in patients with brain metastases","volume":"5","author":"Cagney","year":"2019","journal-title":"JAMA Oncol."},{"issue":"3","key":"2023050411180790600_CIT0010","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijrobp.2019.10.002","article-title":"Nodular Leptomeningeal disease-a distinct pattern of recurrence after Postresection stereotactic Radiosurgery for brain metastases: a multi-institutional study of Interobserver reliability","volume":"106","author":"Turner","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"2023050411180790600_CIT0011","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.nec.2010.08.006","article-title":"Leptomeningeal disease","volume":"22","author":"Groves","year":"2011","journal-title":"Neurosurg Clin N Am."},{"issue":"6","key":"2023050411180790600_CIT0012","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/CCO.0b013e32833de986","article-title":"Leptomeningeal metastasis","volume":"22","author":"Chamberlain","year":"2010","journal-title":"Curr Opin Oncol."},{"issue":"1","key":"2023050411180790600_CIT0013","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11060-007-9340-4","article-title":"Breast cancer leptomeningeal metastasis--the role of multimodality treatment","volume":"84","author":"Rudnicka","year":"2007","journal-title":"J Neurooncol."},{"issue":"2","key":"2023050411180790600_CIT0014","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11060-010-0524-y","article-title":"Meningeal carcinomatosis in breast cancer: prognostic factors and outcome","volume":"104","author":"de\u00a0Azevedo","year":"2011","journal-title":"J Neurooncol."},{"issue":"11","key":"2023050411180790600_CIT0015","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/annonc\/mdq232","article-title":"Survival of breast cancer patients with meningeal carcinomatosis","volume":"21","author":"Gauthier","year":"2010","journal-title":"Ann Oncol."},{"issue":"6","key":"2023050411180790600_CIT0016","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/1097-0142(19910315)67:6<1685::AID-CNCR2820670635>3.0.CO;2-M","article-title":"Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment","volume":"67","author":"Boogerd","year":"1991","journal-title":"Cancer."},{"issue":"12","key":"2023050411180790600_CIT0017","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1002\/1097-0142(19941215)74:12<3135::AID-CNCR2820741212>3.0.CO;2-8","article-title":"Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant","volume":"74","author":"Jayson","year":"1994","journal-title":"Cancer."},{"key":"2023050411180790600_CIT0018","author":"Medicine USNLo","year":"2022"},{"key":"2023050411180790600_CIT0019","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.critrevonc.2019.01.020","article-title":"Leptomeningeal carcinomatosis in patients with breast cancer","volume":"135","author":"Franzoi","year":"2019","journal-title":"Crit Rev Oncol Hematol."},{"issue":"6","key":"2023050411180790600_CIT0020","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/tbj.13433","article-title":"Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes","volume":"25","author":"Znidaric","year":"2019","journal-title":"Breast J."},{"issue":"2","key":"2023050411180790600_CIT0021","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11060-011-0664-8","article-title":"Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment","volume":"106","author":"Kim","year":"2012","journal-title":"J Neurooncol."},{"issue":"12","key":"2023050411180790600_CIT0022","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1002\/cncr.23088","article-title":"Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis","volume":"110","author":"Altundag","year":"2007","journal-title":"Cancer."},{"issue":"16","key":"2023050411180790600_CIT0023","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1200\/JCO.2004.08.095","article-title":"Breast cancer with synchronous metastases: trends in survival during a 14-year period","volume":"22","author":"Andre","year":"2004","journal-title":"J Clin Oncol."},{"issue":"4","key":"2023050411180790600_CIT0024","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/1097-0142(19820215)49:4<759::AID-CNCR2820490427>3.0.CO;2-7","article-title":"Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients","volume":"49","author":"Wasserstrom","year":"1982","journal-title":"Cancer."},{"issue":"2","key":"2023050411180790600_CIT0025","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jns.2004.05.008","article-title":"Leptomeningeal metastasis: survival and prognostic factors in 155 patients","volume":"223","author":"Herrlinger","year":"2004","journal-title":"J Neurol Sci."},{"issue":"11","key":"2023050411180790600_CIT0026","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00432-010-0831-x","article-title":"Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis","volume":"136","author":"Oechsle","year":"2010","journal-title":"J Cancer Res Clin Oncol."},{"issue":"18","key":"2023050411180790600_CIT0027","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1212\/WNL.0b013e3181dc1a69","article-title":"Leptomeningeal metastases in the MRI era","volume":"74","author":"Clarke","year":"2010","journal-title":"Neurology."},{"issue":"4","key":"2023050411180790600_CIT0028","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2174\/157339411797642597","article-title":"Leptomeningeal metastasis: challenges in diagnosis and treatment","volume":"7","author":"Leal","year":"2011","journal-title":"Curr Cancer Ther Rev."},{"issue":"9","key":"2023050411180790600_CIT0029","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/neuonc\/nou089","article-title":"Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials","volume":"16","author":"Chamberlain","year":"2014","journal-title":"Neuro Oncol."},{"issue":"6","key":"2023050411180790600_CIT0030","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/neuonc\/noaa030","article-title":"Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases","volume":"22","author":"Kaufmann","year":"2020","journal-title":"Neuro Oncol."},{"key":"2023050411180790600_CIT0031","author":"Batool"},{"issue":"3","key":"2023050411180790600_CIT0032","doi-asserted-by":"crossref","first-page":"100150","DOI":"10.1016\/j.esmoop.2021.100150","article-title":"Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database","volume":"6","author":"Carausu","year":"2021","journal-title":"ESMO Open."},{"issue":"42","key":"2023050411180790600_CIT0033","doi-asserted-by":"crossref","first-page":"73312","DOI":"10.18632\/oncotarget.20272","article-title":"Leptomeningeal disease: current diagnostic and therapeutic strategies","volume":"8","author":"Nayar","year":"2017","journal-title":"Oncotarget."},{"issue":"1","key":"2023050411180790600_CIT0034","first-page":"vdab181","article-title":"Quantitative cerebrospinal fluid circulating tumor cells are a potential biomarker of response for proton craniospinal irradiation for leptomeningeal metastasis","volume":"3","author":"Wijetunga","year":"2021","journal-title":"Neurooncol Adv."},{"issue":"5","key":"2023050411180790600_CIT0035","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/neuonc\/noz012","article-title":"Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications","volume":"21","author":"Boire","year":"2019","journal-title":"Neuro Oncol."},{"issue":"6","key":"2023050411180790600_CIT0036","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1158\/1078-0432.CCR-06-2478","article-title":"Brain metastases: the HER2 paradigm","volume":"13","author":"Lin","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"10","key":"2023050411180790600_CIT0037","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/cncr.23930","article-title":"Sites of distant recurrence and clinical outomes in patients with metastatic triple-negative breast cancer: high incidence of\u00a0central nervous system metastases","volume":"113","author":"Lin","year":"2008","journal-title":"Cancer."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noac249\/47465189\/noac249.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/25\/5\/973\/50196069\/noac249.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/25\/5\/973\/50196069\/noac249.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T12:37:35Z","timestamp":1683203855000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/25\/5\/973\/6823872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,11,11]]},"published-print":{"date-parts":[[2023,5,4]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noac249","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2022,11,11]]}}}